Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT-301 in CKD Stage IV
NCT04913272Phase 2Suspended
- Sponsor
- Kibow Biotech
- Start
- Jun 2021
- Primary completion
- Sep 2025
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing KT-301 with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events at 6 months and Change in Estimated Glomerular Filtration Rate at 6 months. Started Jun 2021; status: suspended.
02
Drugs
KT-301
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04913272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04913272.